|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Allowance for doubtful accounts | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Receivables, Net, Current | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Assets held for sale (Note 3) | ||||||||||||||||||||
| Derivative assets | ||||||||||||||||||||
| Other current assets and deferred charges | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Investments | ||||||||||||||||||||
| Property, plant, and equipment | ||||||||||||||||||||
| Accumulated depreciation, depletion, and amortization | ||||||||||||||||||||
| Property, plant, and equipment – net | ||||||||||||||||||||
| Intangible assets – net | ||||||||||||||||||||
| Regulatory assets, deferred charges, and other | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Liabilities held for sale (Note 3) | ||||||||||||||||||||
| Derivative Liability, Current | ||||||||||||||||||||
| Accrued and other current liabilities | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Commercial paper | ||||||||||||||||||||
| Long-term debt due within one year | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Deferred income tax liabilities | ||||||||||||||||||||
| Regulatory liabilities, deferred income, and other | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock ($1 par value; 30 million shares authorized at June 30, 2026 and December 31, 2025; 35 thousand shares issued at June 30, 2026 and December 31, 2025) | ||||||||||||||||||||
| Common stock ($1 par value; 1,470 million shares authorized at June 30, 2026 and December 31, 2025; 1,262 million shares issued at June 30, 2026 and 1,261 million shares issued at December 31, 2025) | ||||||||||||||||||||
| Capital in excess of par value | ||||||||||||||||||||
| Retained deficit | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Treasury stock, at cost (39 million shares at June 30, 2026 and December 31, 2025 of common stock) | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Noncontrolling interests in consolidated subsidiaries | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities and equity | ||||||||||||||||||||
Loading...
